Drug updated on 5/8/2024
Dosage Form | Injection (intramuscular; 600 mg/3mL, 400 mg/2mL) |
Drug Class | HIV-1 integrase strand transfer inhibitor and HIV-1 non-nucleoside reverse transcriptase inhibitor |
Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated as a complete regimen for the treatment of HIV-1 infection in adults and adolescents 12 years of age and older and weighing at least 35 kg to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA <50 copies/mL) on a stable antiretroviral regimen with no history of treatment failure and with no known or suspected resistance to either cabotegravir or rilpivirine.
Summary
- Cabotegravir/rilpivirine (Cabenuva) is indicated for the treatment of HIV-1 infection in adults who are virologically suppressed on a stable antiretroviral regimen with no history of treatment failure and no known or suspected resistance to either cabotegravir or rilpivirine.
- Two systematic reviews/meta-analyses were reviewed, which included studies that reported efficacy and safety data on long-acting antiretrovirals intervention in people living with HIV.
- The first review found that cabotegravir/rilpivirine demonstrated safety profiles comparable to those of placebo regarding adverse event-related withdrawal, suggesting it was well-tolerated by patients.
- In terms of effectiveness, this same review showed that cabotegravir had better effects on preventing HIV-1 than tenofovir disoproxil fumarate-emtricitabine; moreover, when combined with rilpivrine as Cabenuva, it maintained high levels (80.9%) of virological suppression even after 5 years use among both treatment-naive and experienced patients.
- According to questionnaires cited in the first review document more than 85% people living with HIV favored long acting antiretrovirals like Cabenuva over daily oral drugs due its convenience and sustained viral suppression ability.
- The second review also confirmed favorable safety profile for both CAB-LA and RPV-LA similar to placebo alongwith promising pharmacokinetic profiles indicating their potential preventive efficacy against HIV-1 infection currently being evaluated further in Phase 3 trials.
Product Monograph / Prescribing Information
Document Title | Year | Source |
---|---|---|
Cabenuva (cabotegravir/rilpivirine) Prescribing Information. | 2023 | ViiV Healthcare, Research Triangle Park, NC |
Health Technology Assessments
Systematic Reviews / Meta-Analyses
Clinical Practice Guidelines
Document Title | Year | Source |
---|---|---|
Updated treatment recommendation on use of cabotegravir and rilpivirine for people with HIV from the IAS-USA guidelines panel. | 2024 | Journal of the American Medical Association |